leadf
logo-loader
viewOncimmune

Oncimmune Holdings' reports 'a year of opportunities' with EarlyCDT lung screening technology

Oncimmune Holdings PLC's (LON:ONC) Adam Hill talks to Proactive London's Katie Pilbeam about their full year results.

Hill talks through the numbers which include income for the year of £715k (2019: £220k) excluded additional contract income of £511k signed and invoiced immediately before year end, and paid in July, bringing total invoiced income to £1.2M.

He also talks about the the opportunities after revealing plans to commercialise the EarlyCDT lung screening technology and its ImmunoINSIGHTS service.

Hill explains the key landmarks, which include an agreement with a firm called Biodesix, which is currently recruiting 2000 patients to eventually commercialise the potential of EarlyCDT Lung in screening lung nodules.

Quick facts: Oncimmune

Price: 165 GBX

AIM:ONC
Market: AIM
Market Cap: £104.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Oncimmune Holdings' collaborate with US based Augmenta Bioworks to profile...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive London about their master service agreement with California-based immunotherapy specialist Augmenta Bioworks. This collaboration will profile patient plasma samples and assess treatment candidates discovered using the latter’s...

3 weeks, 1 day ago

2 min read